AG
VYGR icon

Aperio Group’s Voyager Therapeutics VYGR Stock Holding History

Aperio Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$81K Sell
11,266
-1,539
-12% -$14.8K ﹤0.01% 2388
2020
Q3 		$137K Buy
+12,805
New +$150K ﹤0.01% 2284
2019
Q3 		– Sell
-14
Closed – – 2757
2019
Q2 		$0 Buy
+14
New +$320 ﹤0.01% 3042

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aperio Group's VYGR Position: Q4 2020 in Review

Aperio Group reduced its Voyager Therapeutics (VYGR) stake by 12% in Q4 2020, selling an estimated $14.8K and leaving 11,266 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Aperio Group first reported a position in VYGR in Q2 2019 and has held it in 3 quarters since. The position peaked at $137K in Q3 2020. 101 funds tracked by Wall St. Rank hold VYGR as of Q4 2020.

  • Aperio Group held 11,266 shares of Voyager Therapeutics worth $81K as of Q4 2020.
  • Aperio Group sold 1,539 Voyager Therapeutics shares in Q4 2020, an estimated $14.8K.
  • Voyager Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2388 holding.
  • Aperio Group first reported a position in Voyager Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • Aperio Group's Voyager Therapeutics position peaked at $137K in Q3 2020.
  • 101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.